161 related articles for article (PubMed ID: 12121939)
1. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus.
Ono-Nita SK; Kato N; Shiratori Y; Carrilho FJ; Omata M
Antimicrob Agents Chemother; 2002 Aug; 46(8):2602-5. PubMed ID: 12121939
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.
Ono-Nita SK; Kato N; Shiratori Y; Lan KH; Yoshida H; Carrilho FJ; Omata M
J Clin Invest; 1999 Jun; 103(12):1635-40. PubMed ID: 10377169
[TBL] [Abstract][Full Text] [Related]
3. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.
Ono SK; Kato N; Shiratori Y; Kato J; Goto T; Schinazi RF; Carrilho FJ; Omata M
J Clin Invest; 2001 Feb; 107(4):449-55. PubMed ID: 11181644
[TBL] [Abstract][Full Text] [Related]
4. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.
Gutfreund KS; Williams M; George R; Bain VG; Ma MM; Yoshida EM; Villeneuve JP; Fischer KP; Tyrrel DL
J Hepatol; 2000 Sep; 33(3):469-75. PubMed ID: 11020004
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
6. Perspectives for the treatment of hepatitis B virus infections.
De Clercq E
Int J Antimicrob Agents; 1999 Jul; 12(2):81-95. PubMed ID: 10418752
[TBL] [Abstract][Full Text] [Related]
7. Subclones of drug-resistant hepatitis B virus mutants and the outcome of breakthrough hepatitis in patients treated with lamivudine.
Kumashiro R; Kuwahara R; Ide T; Koga Y; Arinaga T; Hisamochi A; Ogata K; Tanaka K; Sata M
Intervirology; 2003; 46(6):350-4. PubMed ID: 14688451
[TBL] [Abstract][Full Text] [Related]
8. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.
Fu L; Cheng YC
Antimicrob Agents Chemother; 2000 Dec; 44(12):3402-7. PubMed ID: 11083647
[TBL] [Abstract][Full Text] [Related]
9. Novel nucleoside analogue FNC is effective against both wild-type and lamivudine-resistant HBV clinical isolates.
Zhou Y; Zhang Y; Yang X; Zhao J; Zheng L; Sun C; Jiang J; Yang Q; Wang Q; Chang J
Antivir Ther; 2012; 17(8):1593-9. PubMed ID: 22910281
[TBL] [Abstract][Full Text] [Related]
10. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.
Delaney WE; Miller TG; Isom HC
Antimicrob Agents Chemother; 1999 Aug; 43(8):2017-26. PubMed ID: 10428929
[TBL] [Abstract][Full Text] [Related]
11. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.
Levine S; Hernandez D; Yamanaka G; Zhang S; Rose R; Weinheimer S; Colonno RJ
Antimicrob Agents Chemother; 2002 Aug; 46(8):2525-32. PubMed ID: 12121928
[TBL] [Abstract][Full Text] [Related]
12. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
13. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.
Torresi J; Earnest-Silveira L; Civitico G; Walters TE; Lewin SR; Fyfe J; Locarnini SA; Manns M; Trautwein C; Bock TC
Virology; 2002 Jul; 299(1):88-99. PubMed ID: 12167344
[TBL] [Abstract][Full Text] [Related]
14. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
[TBL] [Abstract][Full Text] [Related]
15. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.
Yatsuji H; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Iwao E; Fujimoto Y; Ochi H; Abe H; Maekawa T; Tateno C; Yoshizato K; Suzuki F; Kumada H; Chayama K
Antimicrob Agents Chemother; 2006 Nov; 50(11):3867-74. PubMed ID: 16982790
[TBL] [Abstract][Full Text] [Related]
16. Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate.
Zhang Y; Zhang H; Zhang J; Zhang J; Guo H
Antiviral Res; 2019 May; 165():47-54. PubMed ID: 30902704
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates.
Zhou YB; Wang YF; Zhang Y; Zheng LY; Yang XA; Wang N; Jiang JH; Ma F; Yin DT; Sun CY; Wang QD
Eur J Pharmacol; 2012 May; 683(1-3):10-5. PubMed ID: 22387093
[TBL] [Abstract][Full Text] [Related]
18. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy.
Zhang X; Liu C; Gong Q; Zhang S; Zhang D; Lu Z; Wang Y
J Gastroenterol Hepatol; 2003 Dec; 18(12):1353-7. PubMed ID: 14675262
[TBL] [Abstract][Full Text] [Related]
19. Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model.
Zhang J; Wang Y; Peng Y; Qin C; Liu Y; Li J; Jiang J; Zhou Y; Chang J; Wang Q
Braz J Infect Dis; 2018; 22(6):477-486. PubMed ID: 30586543
[TBL] [Abstract][Full Text] [Related]
20. Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.
Walters KA; Tipples GA; Allen MI; Condreay LD; Addison WR; Tyrrell L
Antimicrob Agents Chemother; 2003 Jun; 47(6):1936-42. PubMed ID: 12760870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
